We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock

Delisted

SRRA was delisted on the 30th of June, 2022.

50 hedge funds and large institutions have $140M invested in Sierra Oncology, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 12

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

6% more funds holding

Funds holding: 4750 (+3)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

41% less capital invested

Capital invested by funds: $240M → $140M (-$99.2M)

Holders
50
Holders Change
+3
Holders Change %
+6.38%
% of All Funds
1.33%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
13
Increased
16
Reduced
12
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Federated Hermes
51
Federated Hermes
Pennsylvania
-$2.26M -3,750 Closed
CS
52
Candriam SCA
Luxembourg
-$1.07M -1,780 Closed
CC
53
Caxton Corporation
New Jersey
-$688K -1,143 Closed
OPPM
54
Opus Point Partners Management
New York
-$451K -750 Closed
RG
55
Redmile Group
California
-$373K -620 Closed
Citadel Advisors
56
Citadel Advisors
Florida
-$365K -607 Closed
NC
57
Nexthera Capital
New York
-$301K -500 Closed
WMSA
58
Weiss Multi-Strategy Advisers
New York
-$150K -250 Closed
PAM
59
Panagora Asset Management
Massachusetts
-$27K -45 Closed
IA
60
IFP Advisors
Florida
-$4K -6 Closed

SRRA Hedge Fund Activity: Q1 2016 in Review

50 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2016, worth a combined $140M — down 41% from $240M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new SRRA positions and 10 closed out — a net gain of 3 holders — while 16 added to existing stakes and 12 trimmed.

The largest buyer was Deerfield Management, adding an estimated $9.66M. The largest seller was OrbiMed, cutting an estimated $2.93M.

  • 50 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2016, up from 47 in Q4 2015.
  • Funds reported $140M of Sierra Oncology, Inc. Common Stock stock for Q1 2016, down 41% quarter-over-quarter.
  • 13 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2016 and 10 closed out, a net change of +3 holders.
  • The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2016 was Deerfield Management, an estimated $9.66M added.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q1 2016 was OrbiMed, an estimated $2.93M sold.

Based on aggregated 13F filings for Q1 2016.